Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.

NCT03773367 is registered in ClinicalTrials.gov with Lund University Hospital as lead sponsor.

NCT NCT03773367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03773367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.
Lead sponsor
Lund University Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 14, 2018
Completion date
November 30, 2026
Enrollment
60 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

resectable gastric and gastroesophageal junction adenocarcinoma